Latest news
US FDA accepts supplemental Biologics License Application for Merck’s Enflonsia - PMLiVEPMLiVE · Fri, 07 Aug 2026 10:55:00 GMTFDA Accepts Merck's Application to Expand Enflonsia into Second RSV Season - BioPharm InternationalBioPharm International · Thu, 06 Aug 2026 16:59:38 GMTFDA Accepts sBLA for Clesrovimab-cfor in Second RSV Season - hcplive.comhcplive.com · Thu, 06 Aug 2026 16:30:47 GMTFDA accepts application to expand Merck's RSV antibody ENFLONSIA into new season - The Pharma LetterThe Pharma Letter · Thu, 06 Aug 2026 14:35:24 GMTFDA accepts application to expand clesrovimab-cfor use to high-risk children in second RSV season - Contemporary PediatricsContemporary Pediatrics · Thu, 06 Aug 2026 14:18:27 GMTFDA accepts Merck's sBLA for Enflonsia to cover second RSV season - StreetInsiderStreetInsider · Thu, 06 Aug 2026 11:58:23 GMTU.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season - Yahoo Finance AustraliaYahoo Finance Australia · Thu, 06 Aug 2026 10:45:00 GMTFDA approves Moderna's mRNA flu vaccine after initial pushback - CBS NewsCBS News · Thu, 06 Aug 2026 03:07:00 GMT